

Rec'd PCT/PTO 15 OCT 2001

Attorney Docket No.: 5559.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bojsen et al.

Serial No.: 09/856,819

Group Art Unit: To Be Assigned

Filed: May 24, 2001

Examiner: To Be Assigned

For: Lipolytic Enzyme Variants

#1D/C
Plunkett
3/23/03

NE

PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO FILE MISSING PARTS
AND TO NOTICE TO COMPLY WITH SEQUENCE RULESPage
Numbers &
line
don't
matchBox PCT
Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Sequence Rules dated July 17, 2001, please amend the above-identified application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE SPECIFICATION:

Please add the two attached pages to the specification at the end of page 43.

Please replace the paragraph on page 9, lines 4-9, with:

--Alternatively, the variant may carry a peptide extension at the C-terminal and/or the N-terminal. The C-terminal extension may consist of 1-10 amino acid residues, e.g. A, P, AG, DG, PG, AGG, PVGF (SEQ ID. NO. 15), AGRF (SEQ ID. NO. 16), PRGF (SEQ ID. NO. 17), AGGF (SEQ ID. NO. 18) or AGGFS (SEQ ID. NO. 19); or it may consist of 40-50 residues, e.g., consisting of the 48 C-terminal residues of the *Fusarium oxysporum* lipase GGF SWRRYRSAESVDKRATMTDAELEKKLNSYVQMD KEYVKNNQARS (SEQ ID. NO. 20). The C-terminal extension may increase the phospholipase activity.--

Please replace the paragraph on page 10, lines 24-31, with: